Olive Leaf Extracts in the Control of Cardiovascular Risk
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1000 participants.
Also called NCT05297110
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose prevention
- Phase
- Phase 2/3
- Enrolled
- 1,000 participants
- Sponsor
- Registry
-
NCT05297110
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Tunisia
- Registry status
- Unknown status
Technical summary
Registry record NCT05297110. Randomized; single masking; primary purpose prevention. Start 2021-08-01 (actual); primary completion 2023-11-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Olive Leaf Extracts in the Control of Cardiovascular Risk
- Acronym
- Atherolive
- Condition
- Diabetes Mellitus, Type 2
- Condition
- Hypertension
- Intervention (Drug)
- atherolive
- Lead sponsor
- University of Monastir
Record details
- Record id
cardio:ct-nct05297110- Content hash
60ddd36fb8b82c9dab8870c2925bb40169ff93668fff73f608503e0e88c474ff